Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Contract Research
Return to: PBR Home | Contract Research & Services | Contract Research | Suppliers

PRA Health Sciences - Drug Development Solutions News

PRA Health Sciences - Drug Development Solutions

PRA Health Sciences, INC. Reports Second Quarter 2015 Results and Provides Updated Guidance for 2015 • $336.5 million of service revenue in the second quarter; 12% constant currency growth compared to the second quarter of 2014. • $61.3 million of Adjusted EBITDA in the second quarter; 35% growth compared to the second quarter of 2014. • Second quarter Adjusted Net Income per share increased 37% to $0.47 per share and Adjusted Net Income increased 112% to $29.7 million compared to the second quarter of 2014. • Second quarter GAAP Net Income was $12.4 million or $0.20 per diluted share Guidance for 2015 diluted Adjusted Net Income per share raised to $1.75-$1.85 from $1.62-$1.72
View press release
PRA Health Sciences Launches New Initiative To Bolster Workforce PRA Health Sciences (PRA) (NASDAQ: PRAH) is looking to hire new talent. To help attract potential employees from around the world, PRA, a leading global contract research organization (CRO), is launching a new Candidate Experience initiative. Just as PRA is finding innovative ways to improve the clinical development process, it is also developing creative strategies to meet the ever-growing need to identify highly skilled clinical research employees.
View press release
PRA Named Clinical Company of the Year PRA Health Sciences (PRA) is pleased to announce that it was once again recognized as the Best Clinical Company of the Year. PRA received the award at the PharmaTimes Clinical Researcher of the Year Americas ceremony in Cary, North Carolina. This award follows PRA’s recognition as the Best International Clinical Company of the Year which was announced earlier this year in London.
View press release
PRA Continues the Transformation of Clinical Trials with Predictivv PRA Health Sciences, a leading global contract research organization, today announced its new Predictivv™ platform, the beginning of an entirely new approach on the role technology will play in the future of clinical development. The Predictivv™ platform will be a fully integrated solution for designing, planning and optimizing the management of global clinical studies. Designed around a unified platform that harmonizes data, processes, and people across every aspect of a clinical study, Predictivv™ will enable unprecedented adaptive intelligence and decision support for the ever-increasing complexities of the clinical development process.
View press release
PRA Sponsors Russian Regional Quality Assurance Forum PRA Health Sciences (PRA) is pleased to sponsor the first meeting of Quality Assurance (QA) experts in Russia. The Russian Regional Research Quality Association (RQA) Forum will facilitate knowledge sharing and the exchange of ideas and opinions in the QA community.
View press release
PRA Health Sciences, inc Reports First Quarter 2015 Results $332.0 million of service revenue in the first quarter; 10% constant currency service revenue growth compared to the first quarter of 2014.
View press release
PRA is Named International Clinical Company Of The Year PRA Health Sciences (PRA) is pleased to announce that it was named Clinical Company of the Year at the International Clinical Researcher of the Year award ceremony in London. This is the second year in a row that PRA has won this prestigious award. PRA also swept the Clinical Team of the Year category. PRA winners include:
View press release
PRA Health Sciences To Add New Jobs In Swansea PRA Health Sciences (PRA), a leading global clinical research organization, is expanding its business in Swansea with the creation of 87 new jobs. The expansion will be supported by £990,060 of business finance from the Welsh Government enabling PRA to grow its local workforce to 280 by December 2017.
View press release
PRA Health Sciences, Inc. Reports 4th Quarter and Full Year 2014 Results and 2015 Guidance PRA Health Sciences, Inc. reported its financial results for the fourth quarter ended December 31, 2014.
View press release
PRA Health Sciences Expands Global Phase I Patient Strategy PRA Health Sciences (PRA) is enhancing its global Phase I patient strategy and increasing its clinical footprint with the expansion of its Early Development Services (EDS). These initiatives are being undertaken in response to market demand to include patients as early as possible in early phase clinical trial development and include:
View press release
PRA Health Sciences Files for Initial Public Offering PRA Health Sciences, Inc. announced today that it has filed a registration statement on Form S-1 with the US Securities and Exchange Commission (SEC) relating to a proposed initial public offering ('IPO') of shares of its common stock by PRA Health Sciences and an affiliate of Kohlberg Kravis Roberts & Co. L.P. (the 'selling stockholder'). The number of shares to be offered and the price range has not yet been determined.
View press release
PRA Health Sciences Expands in Pennsylvania Blue Bell, Pennsylvania will soon be home to PRA Health Sciences' largest office worldwide. PRA, a leading global contract research organisation (CRO), is relocating employees from its Horsham and Fort Washington locations into new modern class A+ office space in Blue Bell. The new office marks the first phase of the relocation plan.
View press release
Q&A: Rodeina Challand, Executive Director Biosimilar Development on the Naming of Biosimilars - the INN Debate With the publication of the WHO draft proposal for the naming of biologics, what is the potential impact on the business of biosimilars?
View press release